The US Food and Drug Administration (FDA) has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the Phase III CATT1 trial for type 1 diabetes (T1D). This ...
The US Food and Drug Administration (FDA) has placed a hold on vTv Therapeutics' cadisegliatin clinical programme. The clinical hold was placed following the identification of an unresolved ...
vTv Therapeutics Inc. (NASDAQ:VTVT) stock is trading lower on Monday. The FDA has placed a clinical hold on the cadisegliatin clinical program, which includes the ongoing CATT1 Phase 3 trial in type 1 ...
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead ...
About four months into the job, Deepa Prasad is resigning from the top perch at vTv Therapeutics after restructuring the company to focus on a late-stage Type 1 diabetes med and laying off a majority ...
CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ...
CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months vTv Therapeutics expects to resume the trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results